AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Protalix BioTherapeutics Director Schwartz Aharon Buys 129000 Shares at $1.6/Share.
ByAinvest
Tuesday, Aug 12, 2025 10:20 pm ET1min read
Protalix BioTherapeutics, Inc. (PLX) has announced that Director Schwartz Aharon has made a significant investment in the company, acquiring 129,000 shares at a price of $1.6 per share on June 10, 2025.
Protalix BioTherapeutics, Inc. (PLX) has seen a significant investment from its Director, Schwartz Aharon. On June 10, 2025, Aharon acquired 129,000 shares of the company at a price of $1.6 per share [3]. This transaction was executed in multiple trades, with prices ranging from $1.60 to $1.575 per share, reflecting a weighted average purchase price of $1.596 [3].Aharon's investment highlights his confidence in Protalix's future prospects, particularly its innovative plant cell-based protein expression system, ProCellEx. This system represents a new method for developing recombinant proteins at an industrial scale, with Protalix being the first company to gain U.S. Food and Drug Administration (FDA) approval for a protein produced through this method [1][2].
Protalix's product pipeline includes several promising candidates, such as PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout, and PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases. The company has also partnered with Pfizer Inc. for the development and commercialization of taliglucerase alfa, a recombinant therapeutic protein for Gaucher disease, and with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio [1][2].
Aharon's investment comes amidst Protalix's preparations to release its financial results for the second quarter of 2025, scheduled for August 14, 2025. Management will host a conference call and webcast to discuss the financial results and provide an update on recent corporate and regulatory developments [1][2].
References:
[1] https://finance.yahoo.com/news/protalix-biotherapeutics-announce-second-quarter-165300213.html
[2] https://www.morningstar.com/news/pr-newswire/20250807ln46644/protalix-biotherapeutics-to-announce-second-quarter-2025-financial-and-business-results-on-august-14-2025
[3] https://www.stocktitan.net/sec-filings/PLX/form-4-protalix-bio-therapeutics-inc-insider-trading-activity-7604d5fffad5.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet